IP Verse

Genentech, Inc. opposition analysis

COMPANY ANALYSIS

Latest oppositions filed by Genentech, Inc.

Patent Number:
EP3177645
Title:
Subcutaneously Administered Bispecific Antibodies For Use In The Treatment Of Cancer
Applicant:
LINDHOFER, HORST, DR.
Opposition Date:
Nov 15, 2021

Latest patents of Genentech, Inc. opposed by its competitors

Patent:
EP2694072
Grant Date:
Aug 7, 2024
Title:
Combinations Of Akt Inhibitor Compounds And Abiraterone, And Methods Of Use
Oppositions:
1
Patent:
EP2784084
Grant Date:
Oct 4, 2023
Title:
Il-17 A/F Heterologous Polypeptides And Therapeutics Uses Thereof
Oppositions:
5
Patent:
EP3597659
Grant Date:
Mar 1, 2023
Title:
Prevention Of Disulfide Bond Reduction During Recombinant Production Of Polypeptides
Oppositions:
9
Patent:
EP3805248
Grant Date:
Jan 18, 2023
Title:
Process For Concentration Of Antibodies And Therapeutic Products Thereof
Oppositions:
2
Patent:
EP3401335
Grant Date:
Jun 30, 2021
Title:
Composition Comprising Antibody That Binds To Domain Ii Of Her2 And Acidic Variants Thereof
Oppositions:
5
Patent:
EP3337812
Grant Date:
Apr 28, 2021
Title:
Method For The Reduction Of Host Cell Proteins In Affinity Chromatography
Oppositions:
4
Patent:
EP3570884
Grant Date:
Sep 30, 2020
Title:
Subcutaneous Her2 Antibody Formulations
Oppositions:
4
Patent:
EP1543038
Grant Date:
Aug 5, 2020
Title:
Protein Purification
Oppositions:
1
Patent:
EP2751285
Grant Date:
Apr 1, 2020
Title:
Diagnostic Markers
Oppositions:
1
Patent:
EP3095793
Grant Date:
Mar 25, 2020
Title:
Reducing Protein A Leaching During Protein A Affinity Chromatography
Oppositions:
2

Competitors of Genentech, Inc.

BAYER INTELLECTUAL PROPERTY GMBH

HOFFMANN EITLE

MAIWALD GMBH

Want to track Genentech, Inc.?

Feel free to send us a message here and we will get back to you